NGG T006
Alternative Names: NGG-T006Latest Information Update: 06 Feb 2025
At a glance
- Originator Next Generation Gene Therapeutics
- Class Antihyperlipidaemics; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Hyperlipoproteinaemia type IIa
Most Recent Events
- 15 Nov 2024 Clinical trials in Hyperlipoproteinaemia type IIa (Parenteral)
- 15 Nov 2024 Preclinical trials in Hyperlipoproteinaemia type IIa in USA (Parenteral)
- 15 Nov 2024 Next Generation Gene Therapeutics plans to submit final Investigational New Drug (IND) application in the coming months (Next Generation Gene Therapeutics pipeline, November 2024)